Want to see GB:OPTI full AI Analyst Report?
OPTI Stock Chart & Stats
5.65 p
0.00 p(0.00%)
At close: 4:00 PM EDT
5.65 p
0.00 p(0.00%)
Day’s Range― - ―
52-Week Range4.50 p - 12.25 p
Previous CloseN/A
Volume2.35K
Average Volume (3M)271.48K
Market Cap
£6.15M
Enterprise Value5.62 p
Total Cash (Recent Filing)£989.00K
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta0.46
Next Earnings
Jul 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding103,300,300
10 Day Avg. Volume539,378
30 Day Avg. Volume271,481
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.09
Price to Sales (P/S)5.86
P/FCF Ratio-3.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthThe sharp increase in 2025 revenue indicates stronger commercial traction for the company’s probiotic and microbiome products. If partner-led launches and customer demand continue, this growth can provide greater operating leverage and support broader market penetration over the next several quarters.
Improving Gross MarginThe substantial gross-margin improvement suggests better unit economics and a more attractive contribution from recent revenue. Maintaining this level would improve the company’s ability to convert commercial growth into cash and could help narrow losses as revenue expands.
Debt-Free Balance SheetThe absence of reported debt reduces refinancing exposure and interest-rate risk, giving OptiBiotix greater flexibility while it develops and commercialises its intellectual property. A conservatively levered balance sheet can also make future strategic funding decisions less constrained by creditors.
Bears Say
Persistent And Widening LossesContinuing losses show that revenue growth has not yet translated into a viable earnings model. With operating costs still scaling faster than revenue, the company may need sustained growth or further cost discipline before its commercial progress produces durable profitability.
Ongoing Operating Cash BurnPersistent negative operating cash flow means the business is not yet self-funding its activities, despite recent revenue growth. Continued cash burn can require external financing or tighter spending, potentially limiting investment capacity and increasing funding pressure if losses persist.
Declining Equity And Negative ReturnsFalling equity and deeply negative returns indicate that cumulative losses are eroding the capital base rather than generating value for shareholders. If this pattern continues, future financing could become more dilutive and the company’s financial resilience may weaken despite having no reported debt.
OptiBiotix Health News
OPTI FAQ
What was OptiBiotix Health PLC’s price range in the past 12 months?
OptiBiotix Health PLC lowest share price was 4.50 p and its highest was 12.25 p in the past 12 months.
What is OptiBiotix Health PLC’s market cap?
OptiBiotix Health PLC’s market cap is £6.15M.
When is OptiBiotix Health PLC’s upcoming earnings report date?
OptiBiotix Health PLC’s upcoming earnings report date is Jul 01, 2027 which is in 284 days.
How were OptiBiotix Health PLC’s earnings last quarter?
OptiBiotix Health PLC released its earnings results on Sep 17, 2026. The company reported -0.015 p earnings per share for the quarter.
Is OptiBiotix Health PLC overvalued?
According to Wall Street analysts OptiBiotix Health PLC’s price is currently Overvalued.
Does OptiBiotix Health PLC pay dividends?
OptiBiotix Health PLC does not currently pay dividends.
What is OptiBiotix Health PLC’s EPS estimate?
OptiBiotix Health PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OptiBiotix Health PLC have?
OptiBiotix Health PLC has 103,300,300 shares outstanding.
What happened to OptiBiotix Health PLC’s price movement after its last earnings report?
OptiBiotix Health PLC reported an EPS of -0.015 p in its last earnings report. Following the earnings report the stock price went down -9.848%.
Which hedge fund is a major shareholder of OptiBiotix Health PLC?
Currently, no hedge funds are holding shares in GB:OPTI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
OptiBiotix Health PLC
OptiBiotix Health Plc, a life sciences enterprise headquartered in York, United Kingdom, specializes in the discovery and advancement of microbiome-modulating technologies. The company formulates distinct microbial strains, innovative compounds, and tailored blends intended for integration into food products, nutritional supplements, and active ingredients. Their groundbreaking work aims to positively influence human physiology and yield substantial health benefits. Among its diverse product portfolio are Slimbiome, a natural ingredient for healthy and satiety-driven weight management, and SlimBiome Medical, a supplemental aid for weight control. Other offerings include CholBiome, a dietary supplement for maintaining healthy cholesterol; Lactobacillus plantarum LPLDL, a probiotic supporting cardiovascular health and overall well-being; LPGOS, a galactooligosaccharide utilized in food applications to mitigate cardiovascular risk factors and enhance general health; WellBiome, a functional fiber and mineral blend designed to bolster gut microbiome diversity and promote wellness; and Sweetbiotix, a sweetener for use in various foods and beverages. Ultimately, OptiBiotix's innovations are designed to prevent and manage prevalent chronic lifestyle diseases, including obesity, high cholesterol, and diabetes. The company was founded in 2012.
Technical Analysis
Evgen Pharma
―
Futura Medical
―
Nuformix Plc
―
Cizzle Biotechnology Holdings PLC
―
SkinBioTherapeutics
―